Repligen

RGEN US Health Care Biotechnology
S&P 400
$165.18
+0.30%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.26.
  • Net profit margin is 6.6%.
  • Current assets comfortably cover current liabilities (current ratio 8.37).

!Watch-points

  • Return on equity is on the lower side at 2.3%.
  • Return on capital employed is on the lower side at 2%.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
7.62

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Piotroski F-ScoreStrong
7 / 8

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 8 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap$9.32B
Current Price$ 165.18
High / Low$ 188.73 / 100.99
Stock P/E226.27396
Book Value$ 37.29
Dividend Yield0%
ROCE1.96%
ROE2.32%
Debt to Equity0.26
Current Ratio8.37
P/B Ratio4.413155
EPS$ 0.86
Debt$542.21M
PAT Margin6.62%
Cash PAT$127.64M
ICR2.44
Educational data only. Not a recommendation to buy, sell or hold any security.